Healthy Skepticism Library item: 13756
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: media release
Worldwide Pharmaceutical Industry Launches Global Health Progress Initiative to Expand Efforts to Improve Health in Developing Countries
IFPMA 2008 Apr 16
http://www.ifpma.org/pdf/2008_04_16_Release_Global_Health_Progress_Launch.pdf
Full text:
Industry supports hundreds of programs helping millions in the developing world and is looking for new partners
Brussels, Geneva, Washington, 16 April 2008 – The worldwide pharmaceutical industry today launched Global Health Progress, an initiative to bring research-based biopharmaceutical companies, global health leaders and policymakers together to build on current partnerships to improve health in the developing world.
Serving as a convening point for the industry and its partners, Global Health Progress will facilitate interaction between the private sector, NGOs and governments to share research and best
practices; raise awareness of global health challenges; and build partnerships to improve global
health.
“Research-based biopharmaceutical companies contribute hugely to health partnerships for the
developing world, through their unique expertise in R&D, regulatory affairs, manufacturing, logistics and many other fields, but we can’t work alone.“ said Dr. Harvey Bale, Director General of IFPMA. “The Global Health Progress initiative should help to expand the range and scope of global health partnerships supported by our industry.”
Global Health Progress today unveiled its web site, www.globalhealthprogress.org, which houses a
database of research-based biopharmaceutical companies’ global health programs, including information on more than 300 partners, 400 programs and ongoing investments of billions of dollars annually in products and man-hours. Featuring stories of health workers on the ground, the site highlights organizations and individuals who are making a difference in global health.
“Research-based biopharmaceutical companies have a longstanding commitment to improving global health – this initiative is a recognition of our unique role and desire to accelerate progress in
fighting disease and strengthening health care systems in developing countries “ said Billy Tauzin,
President and CEO of PhRMA. “As individual companies and a united industry, we recognize that our efforts to address universal health challenges are best realized through partnerships with governments and NGOs that are dedicated to saving lives throughout the world.”
Global Health Progress will leverage strengths in private industry to form new partnerships to further access to medicines; build capacity of health workers in developing nations; advocate for
global action to address health challenges; and continue R&D to develop new tools to fight diseases that plague the developing world.
“Global Health Progress is a groundbreaking initiative to focus the expertise of the pharmaceutical
industry to work with a diverse array of partners to create lasting, sustainable global health
change,” said Brian Ager, Director General of EFPIA. “We recognize that global health challenges
are complex and we want contribute our experience and resources to developing new solutions.”
The Global Health Progress initiative brings research-based biopharmaceutical companies and global
health leaders together to improve health in the developing world. Through meaningful public-private
partnerships with others in the field, including policymakers in the developed and developing world, multilateral institutions, non-governmental organizations, and academia, we can help shape sustainable solutions that improve the health of all people.
Global Health Progress Internet Address: www.globalhealthprogress.org
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 32 national associations and 44 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 2,100 companies committed to researching, developing and bringing to patients new medicines that improve health and the quality of life around the world.
EPFIA Internet Address: www.efpia.eu
The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is the global
non-profit NGO representing the research-based pharmaceutical, biotech and vaccine sectors. Its members comprise 25 leading international companies and 44 national and regional industry associations covering developed and developing countries.
IFPMA Internet Address: www.ifpma.org
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading
pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $44.5 billion in 2007 in discovering and developing new medicines. Industry-wide research and investment reached a record $58.82 billion in 2007.
PhRMA Internet Address: www.phrma.org
PhRMA en Español: www.nuestraphrma.org
For more information, please contact:
Chantal Porges, EFPIA
newsroom@efpia.org
Tel: +32 (2) 626 25 71
Guy Willis, IFPMA
g.willis@ifpma.org
Tel: +41 (22) 338 32 00
Mark Grayson, PhRMA
mgrayson@phrma.org
Tel: +1 (202) 835-3465
